タニアイ マキコ   TANIAI Makiko
  谷合 麻紀子
   所属   医学部 医学科(東京女子医科大学病院)
   職種   准教授
論文種別 原著
言語種別 英語
査読の有無 査読なし
表題 Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors.
掲載誌名 正式名:Annals of hepatology
略  称:Ann Hepatol
ISSNコード:16652681/16652681
掲載区分国外
巻・号・頁 27(2),pp.100670
著者・共著者 HORIUCHI Kentaro, KOGISO Tomomi*, SAGAWA Takaomi, TANIAI Makiko, KOTERA Yoshihito, EGAWA Hiroto, TOKUSHIGE Katsutoshi
発行年月 2022
概要 INTRODUCTION AND OBJECTIVES:Fatty liver disease (FLD) may develop in liver transplant recipients. We investigated the recipient and donor risk factors for FLD development after liver transplantation (LT).METHODS:A total of 108 liver transplant recipients (54 men [50.0%]; median age, 52 [20-68] years) treated from 2011-2020 was enrolled. Three recipients died at < 3 months as a result of infection or blood flow impairment, and were excluded from the long-term FLD study. On evaluation of 88 prospective living donors, fatty liver was observed in 21. The prevalence and risk factors for FLD and survival were evaluated.RESULTS:After LT, 28 of 105 recipients (26.7%) developed FLD. FLD was more common in patients with a high body mass index (BMI) and dyslipidemia (both p < 0.01), primary nonalcoholic steatohepatitis (p = 0.02), after living-donor LT (p = 0.03) and everolimus (EVL) use (p = 0.08). Factors predictive of FLD included EVL use and a high BMI (hazard ratios = 3.00 and 1.34; p = 0.05 and p < 0.01, respectively). Sixteen donors lost 6.5 kg (range: 2.0-16.0 kg) of body weight prior to LT. However, there were no cases of primary non-function, which did not affect the FLD prevalence. Development of FLD did not have a negative impact on LT outcome; the 5-year survival rate was 92.6%.CONCLUSIONS:Recipient factors were more important than donor factors for FLD onset after LT.
DOI 10.1016/j.aohep.2022.100670
PMID 35051631